<DOC>
	<DOCNO>NCT00596245</DOCNO>
	<brief_summary>This open-label , parallel group , single-center study . The study design consist screen treatment period . A total 42 ( approximately 21 sex ) non-smoking healthy volunteer age 18 - 35 .</brief_summary>
	<brief_title>Open-Label , Placebo-Controlled , Parallel Group Study Healthy Volunteers Evaluate Effects Two Single MT 400 Naproxen Sodium Tablets</brief_title>
	<detailed_description>This open-label , parallel group , single-center study . The study design consist screen treatment period . A total 42 ( approximately 21 sex ) non-smoking healthy volunteer age 18 - 35 , select treatment . Potential subject assess exposure ionize radiation work cytotoxic chemical , cell cycle time fall outside range 13 Â± 1.5 hour subject stable chromosomal rearrangement and/or abnormally high background chromosomal aberration frequency . Approximately 30 subject ( 10 per arm ) estimate need analysis .</detailed_description>
	<mesh_term>Naproxen</mesh_term>
	<criteria>1 . Male female subject 1835 year age screen visit 2 . Female subject eligible participation study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; , 2 . Childbearing potential , negative pregnancy test ( urine ) Screening , least one follow applies agree subject : Female sterilization sterilization male partner ; , Any nonmedicated intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ; , Barrier method 3 . Physical status within normal limit age consistent observation Screening 4 . Subject agree remain sequestered site treatment phase study willing able abstain consumption use alcohol , caffeine contain beverage medication duration study 5 . Subject able understand comply study procedure require able willing provide write informed consent prior study procedure perform 1 . History hypersensitivity , allergy , intolerance contraindication use triptan , NSAID aspirin ( include sumatriptan naproxen preparation ) nasal polyps asthma 2 . History presence cardioor cerebrovascular disease ; e.g. , diabetes , hypertension , hyperlipidemia 3 . History presence congenital heart disease , cardiac arrhythmia require medication , clinically significant electrocardiogram abnormality , investigator 's opinion , contraindicate participation study 4 . History evidence ischemic vascular disease include : ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome , sign/symptoms consistent 5 . History evidence central nervous system pathology include stroke and/or transient ischemic attack , epilepsy structural brain lesion lower convulsive threshold , treat antiepileptic drug seizure control within 5 year prior screen 6 . History evidence impair hepatic renal function screen laboratory assessment clinically significant investigator 's opinion 7 . Has clinically significant allergic disease ( exclude nonactive hay fever ) history multiple drug allergy 8 . Evidence macrocytic microcytic anemia deficiency folate B12 Screening 9 . Blood donation excess : 500 mL 14 day ; 1,500 mL 180 day 2,500 mL one year 10 . History bleed disorder 11 . Gastrointestinal disorder , surgery , ulceration , perforation past 6 month ; gastrointestinal bleeding past year ; evidence history inflammatory bowel disease 12 . Females actively try become pregnant breast feed 13 . History evidence alcohol abuse ( 28 unit alcohol ( male ) 21 unit alcohol ( female ) per week ) substance abuse within last year concurrent medical psychiatric condition , investigator 's judgment , likely interfere study conduct , subject cooperation , evaluation interpretation study result , otherwise contraindicate participation clinical trial 14 . Participated investigational drug trial within previous four week 15 . Used tobacco product within past year 16 . Has take medication , include overthe counter , prescription , herbal remedy , within one month first dose ( exception vitamin/mineral supplement ) 17 . Is currently work live environment expose subject cytotoxic chemical ionize radiation , subject medical XRay , vaccination , significant viral bacterial illness within one month Screening 18 . Body Mass Index outside range 1932 kg/m2 Screening 19 . Presence history malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>non-smoking healthy volunteer age 18 - 35</keyword>
</DOC>